Semaglutide, is currently on the market under the brand name, Ozempic, for diabetes and is available in a higher strength under the brand name, Wegovy, for weight loss
Because of the significant risks associated with compounded tirzepatide, the FDA strongly recommends using an FDA-approved tirzepatide drug like Zepbound or Mounjaro when it is available
For comparison, tirzepatide before and after results in men show similar or greater reductions over comparable timeframes, as the dual-agonist mechanism targets both GLP-1 and GIP receptors simultaneously
Other research peptide vendors Some vendors continue to offer tirzepatide
From the starting dose of 2.5 mg , the next step is 5 mg weekly after 4 weeks
Brand-name Mounjaro and Zepbound are supplied as pre-filled, pre-dosed autoinjector pens